Zalcitabine Side‑Effect Neuropathy

What is Zalcitabine side‑effect neuropathy?

Zalcitabine (brand name Hivid) is a nucleoside reverse‑transcriptase inhibitor (NRTI) once used to treat HIV‑1 infection. Like several other NRTIs, it can cause a type of peripheral nerve damage known as drug‑induced neuropathy. This condition is sometimes described simply as “Zalcitabine side‑effect neuropathy.” It manifests as pain, tingling, burning, or weakness in the hands and feet that results from toxicity to the peripheral nervous system.

Although Zalcitabine is no longer a first‑line therapy in most countries, many patients who were treated in the 1990’s and early 2000‑s still experience lingering neuropathic symptoms. Understanding the presentation, causes, and management options is essential for both patients and clinicians.

Common Causes

Neuropathy is a broad term that can arise from many different conditions. When evaluating a patient with suspected Zalcitabine‑related neuropathy, clinicians consider other potential causes, including:

• Other antiretroviral drugs – especially stavudine, didanosine, and lamivudine.
• Diabetes mellitus – chronic hyperglycemia damages peripheral nerves.
• Chronic alcohol use – toxic metabolites impair nerve function.
• Vitamin B12 or folate deficiency – essential for myelin synthesis.
• Autoimmune diseases – such as Guillain‑Barré syndrome or chronic inflammatory demyelinating polyneuropathy (CIDP).
• Chemotherapy agents – e.g., platinum compounds, taxanes, and vincristine.
• Infectious etiologies – hepatitis C, Lyme disease, or leprosy.
• Renal or hepatic failure – accumulation of neurotoxic metabolites.
• Exposure to toxins – heavy metals (lead, mercury) or industrial chemicals.
• Genetic neuropathies – hereditary sensory and autonomic neuropathy (HSAN).

Associated Symptoms

Drug‑induced peripheral neuropathy typically follows a recognizable pattern, but the exact presentation varies from person to person. Common accompanying features include:

• Tingling or “pins‑and‑needles” (paresthesia) in the toes or fingers.
• Burning or electric‑shock like pain, often worsening at night.
• Loss of sensation to temperature or light touch.
• Muscle weakness, especially in the intrinsic hand muscles.
• Reduced reflexes (especially ankle reflexes).
• Gait instability due to loss of proprioception.
• Autonomic signs such as abnormal sweating or changes in blood pressure.
• Psychological impact – anxiety, depression, or sleep disturbance from chronic pain.

When to See a Doctor

Because neuropathy can progress and become disabling, early medical evaluation is important. Seek professional help if you notice any of the following:

• New or worsening numbness, tingling, or pain in the feet or hands.
• Difficulty walking, frequent tripping, or a feeling that the floor is “moving.”
• Loss of temperature or pain sensation, which can increase the risk of injuries.
• Muscle weakness that interferes with daily tasks (e.g., buttoning shirts, holding objects).
• Symptoms that do not improve after stopping Zalcitabine or after dose reduction.
• Signs of depression, insomnia, or severe anxiety related to chronic pain.

Diagnosis

Diagnosing Zalcitabine‑related neuropathy involves a combination of history, physical examination, and targeted testing.

1. Clinical History

• Duration and dosage of Zalcitabine therapy.
• Temporal relationship between drug exposure and symptom onset.
• Other medications, alcohol use, diabetes status, and vitamin levels.

2. Physical Examination

• Sensory testing (light touch, pinprick, vibration).
• Motor strength assessment.
• Reflex testing (especially ankle and knee jerks).
• Gait and balance evaluation.

3. Laboratory & Electrophysiologic Studies

• Blood glucose, HbA1c, and fasting lipid panel to rule out metabolic causes.
• Serum vitamin B12, folate, and thiamine levels.
• Renal and liver function tests.
• Nerve conduction studies (NCS) and electromyography (EMG) – typically show a length‑dependent, symmetric, sensory‑predominant axonal neuropathy in drug‑induced cases.
• Optional skin biopsy for intra‑epidermal nerve fiber density if small‑fiber neuropathy is suspected.

4. Imaging (when indicated)

Magnetic resonance imaging (MRI) of the spine may be ordered if radiculopathy or spinal compression is part of the differential diagnosis.

Treatment Options

Management focuses on three core goals: halt further nerve damage, relieve existing symptoms, and improve function.

1. Discontinue or Switch the Offending Drug

If the patient is still receiving Zalcitabine, the drug should be stopped immediately. Current HIV guidelines recommend alternative agents with a more favorable neuro‑toxicity profile (e.g., tenofovir, emtricitabine, integrase inhibitors). A coordinated switch is essential to maintain viral suppression.

2. Pharmacologic Symptom Relief

• First‑line agents:
  • Gabapentin 300–900 mg three times daily, titrated to effect.
  • Prenatal (pregabalin) 75–150 mg twice daily.
• Second‑line agents:
  • Tricyclic antidepressants (e.g., amitriptyline 10–25 mg at bedtime) – useful for neuropathic pain & sleep.
  • Serotonin‑norepinephrine reuptake inhibitors (e.g., duloxetine 30–60 mg daily).
• Adjuncts: topical lidocaine 5% patches, capsaicin 8% patches, or NSAIDs for breakthrough pain.

3. Physical & Occupational Therapy

Therapists help maintain strength, balance, and fine motor skills. Key interventions include:

• Balance training and gait exercises.
• Grip‑strengthening activities.
• Footwear modifications (soft insoles, wide‑toe shoes) to prevent falls.

4. Nutritional & Supplement Strategies

• Correct vitamin B12 deficiency (cyanocobalamin 1000 µg intramuscularly monthly or high‑dose oral).
• Consider alpha‑lipoic acid 600 mg daily – some studies suggest modest benefit in diabetic neuropathy and may be extrapolated.
• Maintain adequate glycemic control in diabetics (<7% HbA1c if tolerated).

5. Lifestyle Measures

• Quit smoking – nicotine worsens peripheral vasoconstriction.
• Limit alcohol intake to ≤1 drink/day for women, ≤2 drinks/day for men.
• Engage in regular, low‑impact aerobic exercise (walking, swimming) to improve circulation.

Prevention Tips

While Zalcitabine is rarely prescribed today, the principles of preventing drug‑induced neuropathy apply to many medications.

• Baseline assessment before starting any neurotoxic drug – screen for diabetes, vitamin deficiencies, and alcohol use.
• Use the lowest effective dose and limit treatment duration when possible.
• Regular monitoring – assess neuropathic symptoms at each clinic visit; document changes.
• Prompt dose reduction or drug substitution at the first sign of neuropathy.
• Maintain good nutrition – adequate B‑vitamins, omega‑3 fatty acids, and antioxidants.
• Adopt protective foot care – daily inspection, appropriate footwear, and prompt treatment of any skin lesions.
• Educate patients about early warning signs and the importance of reporting them.

Emergency Warning Signs

If any of the following occur, seek emergency medical care (call 911 or go to the nearest emergency department):

• Sudden loss of sensation in a limb with the development of a wound that becomes rapidly red, warm, or foul‑smelling – possible infection or ulceration.
• Rapidly progressing weakness that leads to difficulty breathing, swallowing, or speaking.
• Severe, unrelenting pain not controlled with prescribed medications.
• Signs of autonomic dysfunction such as sudden drop in blood pressure, fainting, or rapid heart rate accompanied by dizziness.
• Any indication of an allergic reaction to new medications (e.g., rash, swelling of face/oropharynx, wheezing).

**References**

• Mayo Clinic. Peripheral neuropathy. https://www.mayoclinic.org/diseases‑conditions/peripheral‑neuropathy/
• CDC. Guidelines for Antiretroviral Therapy in Adults and Adolescents Living with HIV. 2023.
• NIH National Institute of Neurological Disorders and Stroke. Peripheral Neuropathy Fact Sheet. https://www.ninds.nih.gov/
• Cleveland Clinic. Drug‑induced neuropathy. https://my.clevelandclinic.org/health/diseases/
• World Health Organization. Guidelines on the Treatment of HIV. 2022.
• J. R. Gazzaniga et al., “Nucleoside reverse transcriptase inhibitor–associated neuropathy: mechanisms and management,” *Clinical Infectious Diseases*, 2021.